Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint

7/24/24 6:33:58 AM ET

$BIIB

$SAGE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BIIB alert in real time by email

Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint

Get the next $BIIB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIIB
$SAGE

Company	Date	Price Target	Rating	Analyst
Biogen Inc. $BIIB	10/31/2024	$285.00 → $204.00	Overweight → Equal-Weight	Morgan Stanley
Biogen Inc. $BIIB	10/10/2024		Mkt Perform	Raymond James
Sage Therapeutics Inc. $SAGE	10/10/2024		Mkt Perform	Raymond James
Sage Therapeutics Inc. $SAGE	10/4/2024	$10.00 → $4.00	Outperform → Sector Perform	RBC Capital Mkts
Sage Therapeutics Inc. $SAGE	7/30/2024	$16.00 → $10.00	Buy → Hold	TD Cowen
Sage Therapeutics Inc. $SAGE	7/25/2024	$18.00 → $12.00	Overweight → Neutral	JP Morgan
Sage Therapeutics Inc. $SAGE	5/29/2024	$15.00	Neutral	Robert W. Baird
Sage Therapeutics Inc. $SAGE	5/29/2024	$8.00	Sell	Citigroup

More analyst ratings

$BIIB
$SAGE
Financials

Live finance-specific insights

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second quarter Sage and Biogen will not pursue further development of zuranolone in major depressive disorder (MDD) in the U.S. Topline data from the DIMENSION Study in Huntington's Disease (HD) expected late 2024 Cash, cash equivalents and marketable securities of $569 million as of September 30, 2024 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the third quarter ended September 30, 2024. "We are committed to harnessing the full potential of ZURZUVAE as
10/29/24 4:05:00 PM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
Sage Therapeutics, Inc. (NASDAQ:SAGE), today announced that it will host a live webcast on Tuesday, October 29, 2024 at 4:30 p.m. ET to review third quarter 2024 financial results and discuss recent business updates. The webcast can be accessed on the Investor page of Sage's website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics (NASDAQ:SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments ind
10/15/24 6:30:00 AM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheimer's Disease) and DIMENSION (Huntington's Disease) Studies expected in late 2024; primary endpoint for DIMENSION Study adjusted from HD-CAB composite to the Symbol Digit Modalities Test (SDMT) SAGE-324 did not meet the primary endpoint in participants with essential tremor (ET); Sage and Biogen terminated
7/31/24 4:05:00 PM ET
$SAGE
Biotechnology: Pharmaceutical Preparations
Health Care

$BIIB
$SAGE
Press Releases

Fastest customizable press release news feed in the world

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass., Oct. 31, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", )) announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage
10/31/24 8:03:00 PM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD- TOKYO and CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzh
10/30/24 7:30:12 PM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers to predict brain amyloid accumulation in AHEAD study of preclinical AD- TOKYO and CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ", Biogen", )) announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's
10/30/24 7:30:00 PM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward," said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. "With his diverse background in medicine, public health, and business administration, and his extensive experience in medical affairs
10/29/24 8:00:00 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biogen Board Appoints Two New Independent Directors
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
9/12/24 7:30:00 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biogen Appoints Monish Patolawala to its Board of Directors
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company ("3M"), to the Company's Board of Directors (the "Board"), effective January 1, 2024. As an accomplished financial executive, Mr. Patolawala is qualified as an Audit Committee financial expert and may be asked to serve as a member of the Board's Audit Committee. "We are pleased to welcome Monish to the Board as the Company is advancing on its next chapter," said Caroline Dorsa, Chair of the Biogen Board of Directors. "Monish's deep financial expertise and diversified management experience at leadin
11/6/23 7:30:00 AM ET
$BIIB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Sage, Biogen Report Results From Phase 2 KINETIC 2 Study Of SAGE-324 (BIIB124) For Essential Tremor; Did Not Demonstrate Statistically Significant Dose-Response Relationship On Primary Endpoint

Chat with this insight

Recent Analyst Ratings for $BIIB$SAGE

$BIIB$SAGE Financials

Live finance-specific insights

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

$BIIB$SAGE Press Releases

Fastest customizable press release news feed in the world

Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference

$BIIB$SAGE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

SEC Form SC 13G filed by Biogen Inc.

SEC Form SC 13G/A filed by Sage Therapeutics Inc. (Amendment)

$BIIB$SAGE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$BIIB$SAGE SEC Filings

$BIIB$SAGE FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$BIIB$SAGE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$BIIB$SAGE Leadership Updates

Live Leadership Updates

$BIIB$SAGE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$BIIB$SAGE Market Insights

Live Market Insights

Officer Shiferman Gregory L. was granted 5,000 shares, increasing direct ownership by 33% to 19,967 units (SEC Form 4)

New insider Shiferman Gregory L. claimed ownership of 14,967 shares (SEC Form 3)

New insider Minor Lloyd claimed no ownership of stock in the company (SEC Form 3)

SEC Form 8-K filed by Sage Therapeutics Inc.

Biogen Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form 10-Q filed by Biogen Inc.

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

FDA Approval for VUMERITY issued to BIOGEN INC

Biogen downgraded by Morgan Stanley with a new price target

Raymond James resumed coverage on Biogen

Raymond James resumed coverage on SAGE Therapeutics

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

Biogen Board Appoints Two New Independent Directors

Biogen Appoints Monish Patolawala to its Board of Directors

Rowinsky Eric K bought $101,256 worth of shares (455 units at $222.54), increasing direct ownership by 2% to 20,629 units (SEC Form 4)

JP Morgan Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $12

Baird Maintains Neutral on Sage Therapeutics, Lowers Price Target to $13

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target

Recent Analyst Ratings for
$BIIB
$SAGE

$BIIB
$SAGE
Financials

$BIIB
$SAGE
Press Releases

$BIIB
$SAGE
Large Ownership Changes

$BIIB
$SAGE
Insider Trading

$BIIB
$SAGE
SEC Filings

$BIIB
$SAGE
FDA approvals

$BIIB
$SAGE
Analyst Ratings

$BIIB
$SAGE
Leadership Updates

$BIIB
$SAGE
Insider Purchases

$BIIB
$SAGE
Market Insights